前往化源商城

58-40-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL632402
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1981
Volume: 24
Issue: 11
First Page: 1342
Last Page: 1347
DOI: 10.1021/jm00143a016
Standard TypeStandard RelationStandard Value
pKa=3.9
pKa=8.1
pKa=9.3
pKa=9.4
pKa=3.7
pKa=7.8
pKa=9.2
pKa=9.1
pKa=3.9
pKa=8.1
pKa=9.1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: SNCA-p-activity-luciferase
Protocol: PROTOCOL TABLE
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION

1; Cells; 4 uL; Dispense 1500 HEK-293-SNCA-luc cells/well into Greiner 1536-well white / solid bottom tissue culture treated plate. The plate was covered with metal lids with gas-exchange holes.
2; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
3; Compounds; 23 nL; Compounds and controls were transferred via a Kalypsys Pin Tool (Wako USA) equipped with a 1536-slotted pin array. The plate was covered with metal lids with gas-exchange holes.
4; Incubate; 24 hours; Incubate at 37C, 5% CO2, 95% RH.
5; Dispense; 1 uL; Dispense Gly-Phe-7-amino-4-trifluoromethylcoumarin (GF-AFC, prepared at 125 uM in PBS) was added. The plate was covered with metal lids with gas-exchange holes.
6; Incubate; 30 min; Incubate at 37C, 5% CO2.
7; Detector; Fluorescence; Measure fluorescence with ViewLux microplate reader (PerkinElmer) equipped with 405/10 excitation and 540/25 emission filters.
8; Dispense; 3 uL; Dispense ONE-Glo (PerkinElmer) lucifase detection reagent was added to each well. Plates were covered with metal lids with gas-exchange holes.
9; Incubate; 15 min; Incubate at room temperature.
10; Detector; Luminescence; Measure luminescence with ViewLux microplate reader (PerkinElmer) equipped with clear filters.

NOTES (numbers refer to sequence above)
1; HEK-293-SNCA-luc were cultured and suspended in phenol-red free DMEM (4.5 g/L glucose, 25 mM HEPES, cat #21063 (Thermo)).
3; Compounds were added to the assay plate in an 11-point intra plate dose response, 1:3 titration in DMSO with a final concentration range of xxx - yyy uM. Vehicle-only plates, with DMSO being pin-transferred to every well, were inserted at the beginning of screening runs to confirm expected assay performance. Activity was normalized to wells containing medium only (-100% activity, full inhibition) and SNCA-luc cells treated with DMSO vehicle control (0% activity), contained on the same plate as test samples.
10; Signals were analyzed, and dose-response curves were fit using the Hill equation. Compounds in curve classes -1.1, -1.2, -2.1, -2.2 in the SNCA-luc assay were considered active. Compounds were eliminated from further consideration if also active (curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4) in the GF-AFC cytotoxicity assay.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000386857 uMActivity at 0.0001060182 uMActivity at 0.0001896372 uMActivity at 0.0004510146 uMActivity at 0.0007501981 uMActivity at 0.0009728036 uMActivity at 0.00288 uMActivity at 0.00508 uMActivity at 0.00871 uMActivity at 0.015 uMActivity at 0.026 uMActivity at 0.053 uMActivity at 0.079 uMActivity at 0.232 uMActivity at 0.457 uMActivity at 0.692 uMActivity at 1.068 uMActivity at 2.292 uMActivity at 3.859 uMActivity at 11.39 uMActivity at 17.02 uMActivity at 25.62 uMActivity at 57.25 uMActivity at 87.55 uMActivity at 183.4 uMActivity at 286.0 uMCompound QC
Inactive0-6.754.95490.97270.090117.540 0 0 18.940815.9527-1.59161.49698.9408QC'd by Sytravon
Inactive0-5.34.0950.99965.5-7.782340 0 0 1-11.1081-7.5736-7.73535.034-11.1081QC'd by Sytravon
Inactive0-5.154.95490.907-15.92079.540 0 0 117.87255.287413.9021-13.683917.8725QC'd by Sytravon
Activator35.481346.40950Single point of activity-4.452.5884145.9404-0.469131 0 0 035.59340.1678-0.39091.93335.593QC'd by Sytravon
Activator39.810772.26460Single point of activity-4.44.95490.951568.1912-4.073330 0 0 058.01175.8738-9.2278-8.522458.0117QC'd by Sytravon
Activator14.125445.33190Partial curve; partial efficacy; poor fit-4.852.40640.998240.7728-4.55912.41 0 0 040.0933-24.9557-3.884511.525440.0933QC'd by Sytravon
Inactive0-5.754.95490.9291-20.608633.154541 0 0 0-12.846445.456928.2161-28.42-12.8464QC'd by Sytravon
Inactive0-4.354.95490.855-24.2184-0.540 0 0 0-18.932-3.6477-2.4094.988-18.932QC'd by Sytravon
Inactive0-4.73.62720.862515-8.552340 0 0 014.477-2.951-13.7936-5.964614.477QC'd by Sytravon
Inactive0-6.74.95490.66373-16.86440 0 0 08.8169-15.726.3794-6.35998.8169QC'd by Sytravon
Inactive0-4.752.40640.999921.5-2.410141 0 0 020.218433.3778-2.42513.577120.2184QC'd by Sytravon
Inactive0-4.44.95490.81172.5-8.34540 0 0 01.096-8.966-5.5054-11.12091.096QC'd by Sytravon
Activator39.810738.79450Single point of activity-4.44.95490.624141.75572.961230 0 0 036.203921.355-6.3904-4.532536.2039QC'd by Sytravon
Inactive0-6.054.0950.9994-6.05182040 0 0 120.515619.73771.4122-6.293220.5156QC'd by Sytravon
Inactive0-5.24.095110.5-10.168341 0 0 1-15.988436.1362-10.14028.7939-15.9884QC'd by Sytravon
Inactive0-6.51.39050.9999-24.2410.274540 0 0 1-5.5981-4.3546-20.7587-23.9509-5.5981QC'd by Sytravon
Inactive0-6.84.95490.711-2.44592140 0 0 0-3.345317.3219-9.95495.5495-3.3453QC'd by Sytravon
Activator39.810747.8090Partial curve; partial efficacy; poor fit-4.44.95490.521250.23992.43092.40 0 0 043.472230.2363-10.9855-11.514343.4722QC'd by Sytravon
Activator22.387275.50810Partial curve; high efficacy; poor fit-4.651.96730.982996.532421.02432.30 0 0 086.498526.093216.336536.261386.4985QC'd by Sytravon
Inactive0-6.84.95490.7429-1-13.073840 0 0 01.8063-11.31150.8702-5.17571.8063QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL2025124
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2012
Volume: 55
Issue: 4
First Page: 1645
Last Page: 1661
DOI: 10.1021/jm201463v
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Peff=1.2ucm/s
Peff=0.5ucm/s
Peff=14.9ucm/s
Peff=1.7ucm/s
Peff=8.9ucm/s
Peff=1.6ucm/s
Peff=0.9ucm/s
Peff=16ucm/s
Peff=15.9ucm/s
Peff=2.2ucm/s
PeffND(Insoluble)
Peff=15.8ucm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL2449009
Protocol: N/A
Comment: Journal: Pharm Res
Year: 2013
DOI: 10.1007/s11095-013-1232-z
Standard TypeStandard ValueActivity Comment
pKa8.1Basic pKa
pKa9.45Basic pKa
pKa9.7Basic pKa
pKa9.6Basic pKa
pKa9.38Basic pKa
pKa8.06Basic pKa
pKa9.6Basic pKa
pKa9.45Basic pKa
pKa7.4Basic pKa
pKa7.63Basic pKa
pKa10.1Basic pKa
pKa8.65Basic pKa
pKa9.76Basic pKa
pKa8.18Basic pKa
pKa8.2Basic pKa
pKa9.25Basic pKa
pKa10.23Basic pKa
pKa7.94Basic pKa
pKa7.94Basic pKa
pKa8.3Basic pKa
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Pleiotropic ABC efflux transporter of multiple drugs
External ID: CHEMBL1696307
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Antimicrob. Agents Chemother.
Year: 2009
Volume: 53
Issue: 4
First Page: 1516
Last Page: 1527
DOI: 10.1128/aac.00956-08

Target ChEMBL ID: CHEMBL1697658
ChEMBL Target Name: Pleiotropic ABC efflux transporter of multiple drugs
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
4.5IC50=4500nM
11.3IC50=11300nM
1.4IC50=1400nM
4.9IC50=4900nM
17.7IC50=17700nM
1.7IC50=1700nM
1.7IC50=1700nM
3.2IC50=3200nM
400IC50>400000nMOutside typical range
5.1IC50=5100nM
400IC50>400000nMOutside typical range
2.3IC50=2300nM
9.6IC50=9600nM
0.7IC50=700nM
10.3IC50=10300nM
9IC50=9000nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Rattus norvegicus
External ID: CHEMBL797214
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1981
Volume: 24
Issue: 3
First Page: 262
Last Page: 270
DOI: 10.1021/jm00135a006

Target ChEMBL ID: CHEMBL376
ChEMBL Target Name: Rattus norvegicus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard Value
Papp=2.8
Papp=1.8
Papp=2.92
Papp=1.7
Papp=2.15
Papp=2.3
Papp=2.267
Papp=2.67
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3859148
Protocol: N/A
Comment: Journal: Bioorg Med Chem
Year: 2016
Volume: 24
Issue: 21
First Page: 5162
Last Page: 5171
DOI: 10.1016/j.bmc.2016.08.036
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Peff=110'-6 cm/s
Peff=0.910'-6 cm/s
Peff=12.310'-6 cm/s
Peff=0.710'-6 cm/s
Peff=17.810'-6 cm/s
Peff=2.210'-6 cm/s
Peff=16.810'-6 cm/s
Peff=0.710'-6 cm/s
Peff=13.810'-6 cm/s
Peff=6.510'-6 cm/s
PeffNot Determined
Peff=6.710'-6 cm/s
Peff=28.410'-6 cm/s
Peff=26.510'-6 cm/s
Peff=1.410'-6 cm/s
Peff=5.810'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3859151
Protocol: N/A
Comment: Journal: Bioorg Med Chem
Year: 2016
Volume: 24
Issue: 21
First Page: 5162
Last Page: 5171
DOI: 10.1016/j.bmc.2016.08.036
Standard TypeStandard RelationStandard ValueStandard Units
Peff=0.810'-6 cm/s
Peff=0.110'-6 cm/s
Peff=1310'-6 cm/s
Peff=010'-6 cm/s
Peff=1210'-6 cm/s
Peff=2.510'-6 cm/s
Peff=9.310'-6 cm/s
Peff=1.110'-6 cm/s
Peff=8.810'-6 cm/s
Peff=5.310'-6 cm/s
Peff=5.110'-6 cm/s
Peff=1610'-6 cm/s
Peff=1710'-6 cm/s
Peff=1.910'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4422901
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2019
Volume: 163
First Page: 512
Last Page: 526
DOI: 10.1016/j.ejmech.2018.12.013
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
Peff=0.3710'-6 cm/s
Peff=0.7810'-6 cm/s
Peff=18.8710'-6 cm/s
Peff=610'-6 cm/s
Peff=16.410'-6 cm/s
Peff=5.210'-6 cm/s
Peff=0.2410'-6 cm/s
Peff=17.710'-6 cm/s
Peff=0.3710'-6 cm/s
Peff=14.310'-6 cm/s
Peff=5.110'-6 cm/s
Peff=9.2210'-6 cm/s
Peff=0.2610'-6 cm/s
Peff=21.210'-6 cm/s
Peff=22.310'-6 cm/s
Peff=0.6510'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4422943
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2019
Volume: 163
First Page: 512
Last Page: 526
DOI: 10.1016/j.ejmech.2018.12.013
Standard TypeStandard RelationStandard ValueStandard Units
Peff=0.810'-6 cm/s
Peff=0.810'-6 cm/s
Peff=6.510'-6 cm/s
Peff=1210'-6 cm/s
Peff=2.510'-6 cm/s
Peff=9.310'-6 cm/s
Peff=1.110'-6 cm/s
Peff=8.810'-6 cm/s
Peff=5.310'-6 cm/s
Peff=0.110'-6 cm/s
Peff=1610'-6 cm/s
Peff=1710'-6 cm/s
Peff=1.910'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Rattus norvegicus
External ID: CHEMBL783802
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1980
Volume: 23
Issue: 8
First Page: 938
Last Page: 941
DOI: 10.1021/jm00182a022

Target ChEMBL ID: CHEMBL376
ChEMBL Target Name: Rattus norvegicus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
ED50=200umol.kg-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: APP-Toga-CHIKV-nsp2-p
Protocol: PROTOCOL TABLE (as described by Inglese J, Shamu CE and Guy RK. 2007)
SEQUENCE No. (e.g., 1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE; DESCRIPTION.
1; Control / Compound; 20 nL; Echo 655 acoustic dispenser, Greiner 1536-well solid bottom black plate.
2; Enzyme; 4 uL; BioRAPTR FRD liquid dispenser (Beckman Coulter).
3; Incubation; 15 min; room temperature.
4; Reagent; 4 uL; 2.5 uM Peptide 2 substrate.
5; Incubation; 1 hr; room temperature.
6; Detection; Fluorescence; WiewLux microplate reader (PerkinElmer), 525 nm excitation, 598/25 nm emission.

NOTES (numbers refer to sequence numbers above).
1. Briefly, 20 nL DMSO, positive control ZnAc (20nM final concentration), and test compounds were transferred into a 1,536-well solid bottom black plate (789176-F, Greiner One) via Echo 655 acoustic dispenser (Beckman Coulter). For primary screens, compounds were tested at 7 concentrations, 1:3 dilution points ranging from 25 uM to 34 nM. Follow-up confirmatory screens were carried out at 11 concentrations, 1:3 dilution points from 25 uM to 0.42 nM.
2. Four uL nsP2pro enzyme mix (150 nM final concentration) in 10 mM Tris-HCl pH 8.0 with 0.01% Tween 20 assay buffer was dispensed into the plate using a BioRAPTR FRD liquid dispenser (Beckman Coulter).
3. The plate was incubated at room temperature (protected from light) for 15 min
4. Four microliter of peptide 2 substrate (2.5 uM final concentration) in assay buffer was added to the plate.
5. After 1 hour, plates were immediately read on a ViewLux high-throughput CCD imager (Exposure = 10 sec, Gain = High, Speed = Slow, Binning = 2X). The above assay was also incorporated in the NCATS HTS facility41, which allowed for robotic liquid and compound dispensing, microplate handling, and fluorescence reading..

REFERENCE:
Inglese J, Shamu CE and Guy RK, Reporting data from high throughput screening of small molecule libraries, Nature Chemical Biology, 2007, 3(8): 438-441. doi.org/10.1038/nchembio0807-438.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods [1].

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.

Reference:
1. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A. 2006;103(31):11473-11478.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000040000 uMActivity at 0.0000163452 uMActivity at 0.0000320000 uMActivity at 0.0000806082 uMActivity at 0.0001439601 uMActivity at 0.0003895389 uMActivity at 0.0007288991 uMActivity at 0.00154 uMActivity at 0.00290 uMActivity at 0.00454 uMActivity at 0.00833 uMActivity at 0.021 uMActivity at 0.041 uMActivity at 0.095 uMActivity at 0.199 uMActivity at 0.321 uMActivity at 0.689 uMActivity at 1.028 uMActivity at 2.684 uMActivity at 5.101 uMActivity at 10.05 uMActivity at 24.85 uMActivity at 39.21 uMActivity at 78.39 uMActivity at 125.0 uMCompound QC
Inactive000458.411643.591625.884333.42079.110921.639545.688610.891128.395531.312738.991441.655858.4116QC'd by Sytravon
Inactive0004-12.6805-10.7548-9.5107-10.6418-15.9997-12.6805QC'd by Sytravon
Inactive0004-7.1462-9.2235-11.8601-6.118-12.2196-7.1462QC'd by Sytravon
Inactive0-4.754.95490.6661-22.0013-240 0 0 0 0-18.751-10.987-0.99352.3561.2583-18.751QC'd by Sytravon
Inactive0004-11.1249-10.2692-11.5229-11.032-13.325-11.1249QC'd by Sytravon
Inactive0-4.81.88510.5555-23.9168-5.408840 0 0 0 0-18.264-13.0121-2.8407-6.6548-7.1687-18.264QC'd by Sytravon
Inactive0-6.354.95490.9083-3.1815-14.928340 0 0 0 1-10.2909-13.1276-17.0236-1.4012-4.6174-10.2909QC'd by Sytravon
Inactive0-5.950.40.9812-20.7272-0.994240 0 0 0 0-16.0227-4.9952-8.1266-9.7286-14.3153-16.0227QC'd by Sytravon
Inactive0-6.54.95490.6409-9.2158-16.601140 0 0 0 1-12.7654-16.3342-16.1896-6.0131-13.084-12.7654QC'd by Sytravon
Inactive00041.9752.61033.4198-3.47481.76241.975QC'd by Sytravon
Inactive0004-8.2223-0.1456-4.3339-1.582-3.6253-8.2223QC'd by Sytravon
Inactive0-7.254.95490.602-10.0715240 0 0 0 0-12.60110.2325-14.2262-4.5441-8.7364-12.6011QC'd by Sytravon
Inactive0-4.754.50450.9809-24.6554-10.844240 0 0 0 0-22.2129-9.8702-10.3098-11.7375-10.6121-22.2129QC'd by Sytravon
Inactive0-4.754.95490.8409-13.5514240 0 0 0 0-11.2928-1.92764.61061.33364.0275-11.2928QC'd by Sytravon
Inactive0-5.20.50.9077-28.8252-9.445240 0 0 0 0-23.1876-10.7877-12.0613-16.7104-16.3414-23.1876QC'd by Sytravon
Inactive0004-18.3436-16.2788-21.7212-19.8613-16.6894-18.3436QC'd by Sytravon
Inactive0004-5.4025-9.518-0.16940.2848-4.8162-5.4025QC'd by Sytravon
Inactive0004-23.1229-14.0834-13.5556-16.7644-18.8145-23.1229QC'd by Sytravon
Inactive0-4.953.29750.9426-35.5663-15.226240 0 0 0 0-34.2687-12.6885-18.3414-14.0693-16.4909-34.2687QC'd by Sytravon
Inactive0-4.754.95490.7952-15.6253-4.893240 0 0 0 0-13.8544-4.3645-8.5252-3.661-3.9903-13.8544QC'd by Sytravon
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3279828
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1977
Volume: 20
Issue: 3
First Page: 430
Last Page: 439
DOI: 10.1021/jm00213a022
Standard TypeStandard RelationStandard Value
pKa=8.1
pKa=9.5
pKa=9.36
pKa=9.42
pKa=7.9
pKa=9.21
pKa=9.1
pKa=7.9
pKa=8.5
pKa=8.1
pKa=8.1
pKa=9.41
pKa=9.29
pKa=8
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3279830
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1977
Volume: 20
Issue: 3
First Page: 430
Last Page: 439
DOI: 10.1021/jm00213a022
Standard TypeStandard RelationStandard Value
LogP=5.35
LogP=4.68
LogP=3.92
LogP=5.32
LogP=4.47
LogP=3.8
LogP=4.63
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3279829
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1977
Volume: 20
Issue: 3
First Page: 430
Last Page: 439
DOI: 10.1021/jm00213a022
Standard TypeStandard RelationStandard Value
Rm=3.55
Rm=4.51
Rm=4.12
Rm=3.43
Rm=2.74
Rm=4.24
Rm=3.03
Rm=2.17
Rm=2.67
Rm=3.37
Rm=3.19
Rm=2.94
Rm=2.49
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Albumin
External ID: CHEMBL3279832
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1977
Volume: 20
Issue: 3
First Page: 430
Last Page: 439
DOI: 10.1021/jm00213a022

Target ChEMBL ID: CHEMBL3728
ChEMBL Target Name: Serum albumin
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard Value
log K=4.32
log K=3.95
log K=4.58
log K=4.32
log K=4.11
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Albumin
External ID: CHEMBL3279831
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1977
Volume: 20
Issue: 3
First Page: 430
Last Page: 439
DOI: 10.1021/jm00213a022

Target ChEMBL ID: CHEMBL3728
ChEMBL Target Name: Serum albumin
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard Value
logKd=4.67
logKd=5.15
logKd=4.98
logKd=4.54
logKd=4.2
logKd=5.17
logKd=4.41
logKd=4.12
logKd=4.36
logKd=4.78
logKd=4.66
logKd=4.46
logKd=4.21
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Albumin
External ID: CHEMBL3279833
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1977
Volume: 20
Issue: 3
First Page: 430
Last Page: 439
DOI: 10.1021/jm00213a022

Target ChEMBL ID: CHEMBL3728
ChEMBL Target Name: Serum albumin
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard Value
log K=3.8
log K=3.79
log K=3.45
log K=3.99
log K=3.33
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4255024
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2018
Volume: 145
First Page: 431
Last Page: 444
DOI: 10.1016/j.ejmech.2018.01.007
Standard TypeStandard RelationStandard ValueStandard Units
permeability=0.8ucm/s
permeability=0.5ucm/s
permeability=11.4ucm/s
permeability=0.1ucm/s
permeability=11.8ucm/s
permeability=0.1ucm/s
permeability=0.5ucm/s
permeability=17ucm/s
permeability=16.8ucm/s
permeability=0.4ucm/s
permeability=2.4ucm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL655893
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 1981
Volume: 24
Issue: 3
First Page: 262
Last Page: 270
DOI: 10.1021/jm00135a006
Standard TypeStandard RelationStandard Value
Log K=3.91
Log K=3.21
Log K=3.57
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4049964
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2017
Volume: 130
First Page: 139
Last Page: 153
DOI: 10.1016/j.ejmech.2017.02.042
Standard TypeStandard RelationStandard ValueStandard Units
permeability=0.810'-6 cm/s
permeability=0.810'-6 cm/s
permeability=6.510'-6 cm/s
permeability=1210'-6 cm/s
permeability=2.510'-6 cm/s
permeability=9.310'-6 cm/s
permeability=1.110'-6 cm/s
permeability=8.810'-6 cm/s
permeability=5.310'-6 cm/s
permeability=5.110'-6 cm/s
permeability=0.110'-6 cm/s
permeability=1610'-6 cm/s
permeability=1710'-6 cm/s
permeability=1.910'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: ZIK159
Protocol: Assay Protocol Summary:

The medium for SNB-19 cells is composed of RPMI 1640 (ATCC, Cat.# 30-2001), 10% fetal bovine serum (FBS) (GE healthcare Life Sciences, Cat.# SH30071.03), and 1% Pen/Strep (Gibco, Cat.# 15140-122). A Caspase-Glo 3/7 assay kit (catalog number G8092; Promega, Madison, WI) was used to detect caspase-3 activity induced by Zika virus infection in human cells. The reagent mixture was reconstituted as described in the protocol from the manufacturer. Polystyrene tissue culture treated and PDL coated white plates were obtained from Greiner Bio-One (Monroe, NC). Cells were seeded in 384- or 1536-well assay plates and cultured at 37 C with 5% CO2 for 16 to 20 hours. The typical cell seeding density in the 1536-well plate assay is 250 cells/well in 3ul medium for SNB-19 cells in tissue culture treated plates. Compounds were added to cells and incubated for one hour before addition of ZIKV solution to cells (2 FFU/cell). After incubation at 37 C with 5% CO2 for 6 hours, the reagent mixture of Caspase-Glo 3/7 assay kit was added to each well, followed by incubation at room temperature for 30 minutes. The luminescence intensity of the assay plates was measured using a ViewLux plate reader (PerkinElmer). Data were normalized by using the cell-containing wells without ZIKV as a negative control (0% induction of caspase 3/7 activity) and wells containing ZIKV infected cells (Caspase-3 activity induced) as a positive control (100% induction of caspase 3 activity). The percentage inhibitions of the increased Caspase-3 activity by small molecule inhibitors were then calculated.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000311982 uMActivity at 0.0000854986 uMActivity at 0.0001529332 uMActivity at 0.0003637214 uMActivity at 0.0006049985 uMActivity at 0.0007847206 uMActivity at 0.00233 uMActivity at 0.00410 uMActivity at 0.00702 uMActivity at 0.012 uMActivity at 0.021 uMActivity at 0.043 uMActivity at 0.064 uMActivity at 0.189 uMActivity at 0.345 uMActivity at 0.568 uMActivity at 0.973 uMActivity at 1.726 uMActivity at 4.529 uMActivity at 9.061 uMActivity at 15.16 uMActivity at 20.54 uMActivity at 45.68 uMActivity at 92.75 uMActivity at 177.7 uMActivity at 231.2 uMCompound QC
Inactive0-6.57924.95490.3504-2.229914.585140 0 0 0 0 0 0 0 0 0 0-5.356915.474625.14691.32891.457930.092112.8619-9.5062-12.2483-4.443920.4415-5.3569QC'd by BIOMOL
Inactive00040.140559.29224.527917.63713.780410.6882-1.5038-3.37094.203930.3994-1.99860.1405QC'd by BIOMOL
Inactive0-8.32924.95490.7822-3.268722.540 0 0 0 0 0 0 0 0 0 0-5.221915.927728.3896-3.44590.9788-0.6642-4.0601-8.14096.6432-8.9739-5.0251-5.2219QC'd by BIOMOL
Inactive0-7.17923.06540.4254932.145740 0 0 0 0 0 0 0 0 0 135.30295.277541.434433.152350.303620.24367.33299.210316.67199.450714.423135.3029QC'd by BIOMOL
Inactive0-8.37924.95490.35830.9315.540 0 0 0 0 0 0 0 0 0 119.319111.410119.1762-0.614-5.8917-0.005821.4835-3.85571.8137-0.8127-2.822419.3191QC'd by BIOMOL
Activator26.3506106.31810Single point of activity-4.57924.95490.950195.6321-10.685930 0 0 0 0 0 0 0 0 0 089.5669-8.1996-4.634-16.5004-16.3027-20.3551-20.1104-2.4639-1.956-4.3704-4.164789.5669QC'd by BIOMOL
Inactive0-9.02924.95490.39864-15.151240 0 0 0 0 0 0 0 0 0 011.3272-9.70937.84233.37613.399312.5003-0.1871-0.4744-2.70083.131-0.583111.3272QC'd by BIOMOL
Inactive0-4.47920.80.6034-34.4978-440 0 0 0 0 0 0 0 0 0 0-27.0815-0.6401-2.5148-2.2817-11.00811.0964-8.2348-11.6629-9.9639-6.098-9.2602-27.0815QC'd by BIOMOL
Inactive0004-0.534621.15938.357233.008610.588322.210240.91430.450915.303915.248315.763-0.5346QC'd by BIOMOL
Inactive0-7.37924.95490.72140.194224.863440 0 0 0 0 0 0 0 0 0 04.066615.530928.052423.038933.3812-2.1843-9.34578.111511.7564-7.393-1.86714.0666QC'd by BIOMOL
Inactive0004-29.782-16.4018-13.9219-14.5268-17.1479-18.872416.6048-0.8381-12.8788-19.3078-27.9636-29.782QC'd by BIOMOL
Inactive0004-9.6121-3.3856-4.2081-0.1463-6.8307-5.50433.9502-1.1496-1.2765-3.5332-1.7407-9.6121QC'd by BIOMOL
Activator0.331733.60330Complete curve; partial efficacy; poor fit-6.47920.70.714330.0135-3.58981.40 0 0 0 0 0 0 0 0 0 022.2786-3.1933-2.4551-4.04170.021512.07325.324119.20397.398643.355928.542722.2786QC'd by BIOMOL
Inactive0004-9.58580.041-18.54712.7931-0.1637-0.4717-3.0273-11.8154-12.2288-9.8437-6.1918-9.5858QC'd by BIOMOL
Inactive00043.544242.3006-2.999222.3937.6161-4.116332.17070.342-5.177242.8575-0.91733.5442QC'd by BIOMOL
Inactive0-6.37924.95490.3244-0.6421040 0 0 1 0 0 0 0 0 0 15.11119.82912.00793.113638.3079-0.532125.7035-1.3518-3.035-0.42124.22735.1111QC'd by BIOMOL
Inactive0-6.87924.95490.39070.6238.540 0 0 0 0 0 0 0 0 0 17.33186.6121-0.51588.08089.177318.9883-0.89744.13632.4077-2.3975-0.54117.3318QC'd by BIOMOL
Inactive0-7.62922.25260.46726-9.673540 0 0 0 0 0 0 0 0 0 04.0434-5.2371-12.2279-11.2597-1.22923.2718-0.865126.0229-0.0171-0.60298.95184.0434QC'd by BIOMOL
Inactive0004-0.5003-6.954428.7797-7.1636-6.6411.8449-16.4193-9.0529-12.5437-4.3363-10.7171-0.5003QC'd by BIOMOL
Inactive00049.9428-15.654318.1375-12.36-2.562816.0422-19.5863-8.3403-1.4148-7.26780.13079.9428QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Southern Research Institute 靶标:CFTR
External ID: CF Folding
Protocol: A high throughput 384-well microplate based fluorescence assay was developed using HeLa cells engineered to express F508del-CFTR. Cells were maintained in cell culture media (High Glucose DMEM (Gibco) supplemented w/ 10% FBS (Gibco)). For the assay, cells were trypsinized (0.25% Trypsin-EDTA solution (Gibco)) and resuspended in assay media (cell culture media + 1% Pen/Strep (Gibco)) at a density of 320,000 cells per ml. Cells were dispensed to the assay plates (Corning 3712) in 25 ul using a Wellmate (Matrix/Thermo). Plates were incubated overnight at 37C, 5% CO2 and high humidity. The next day, compounds were prepared by making a dilution in assay media to a concentration of either 150 uM or 60 ug/ml (6x) depending on the library being screened. Then 5 ul of the diluted compound was transferred to the assay plate containing the cells. Assay plates were incubated for 24 hours 37C, 5% CO2 and high humidity. Following incubation with the compounds, relative cell number was determined by adding 3 ul of alamarBlue (TREK Diagnostics) and incubating the plates at 37C, 5% CO2 and high humidity, until cell control values reached ~4 million, as measured with a fluorescent intensity protocol on an Envision multimode plate reader (Perkin Elmer) (excitation 535 nm, emission 595 nm wavelengths) . Following the alamarBlue read, the media was removed and the cells were fixed with the addition of 13 ul of 4% paraformaldehyde in PBS (pH 7.4) and incubated for 10 minutes at room temperature. Plates were washed twice with PBS to remove the fixative. Cells were permeabilized with the addition of blocking solution (PBS, 0. 1% Triton X-100, 10 mg/ml BSA) and incubated at room temperature for 30 minutes. The blocking solution was removed and the primary antibody mixture was added in 13ul (Antibodies UNC570 and UNC596; CFF Therapeutics, Inc., Bedford, MA) at a 1/5000 dilution of each antibody in blocking solution. Plates were then incubated over night at 4oC. Primary antibody was removed by washing three times with 50 ul of wash solution (PBS, 0.1% Triton X-100) with at least 5 minutes between wash cycles. Secondary antibody (Alexa 488 anti-mouse IgG Invitrogen) was then added in a volume of 13 ul (1/1000 dilution in blocking solution) and incubated for two hours at room temperature in the dark. To remove excess secondary antibody, plates were washed three times with 50 ul of wash solution and one time with 50 ul of PBS. Plates were read from the bottom using a fluorescent intensity protocol on an Envision multimode plate reader (485 nm excitation and 535 nm emission).
To minimize the disruption of the cell monolayer during the numerous washes, the following process was used. The removal of media or other reagents for the wells of the microtiter plate was done using a Biomek FX (Beckman, Fullerton CA) with a 384 tip multichannel head. Aspiration was done at a slow rate following the liquid level with the tip positioned in the top right corner of the well. All solution additions, starting with the fixative, were done with a Matrix Wellmate. Again to avoid disturbing the cell monolayer, the plate offset was adjusted so that the liquid dispensed to the left wall of the well rather than directly on the cell monolayer.
For the screen, approximately ten thousand compounds from a mix of FDA and diverse libraries (MicroSource Pharmacon-1600 (FDA), Enzo (FDA), Selleck (FDA) and Enamine) were tested at a final concentration 25 uM (Enzo, Selleck & MS Pharmakon) or 10 ug/ml (Enamine 30K diversity set). The proteasome inhibitor ALLN was used as the positive control (50 uM) and 100 uM Hyamine was used as a viability control on all microtiter plates. All wells including the cell controls contained 0.5% DMSO. In-plate controls were used to normalize the data and results were reported as fold increase above the cell control and normalized to relative cell number derived from the alamarBlue data.
Ninety six compounds identified in the single dose screen were evaluated further in dose response. Compound high dose was twice the screening concentration and a ten point series of two fold dilutions were done for each compound. DMSO concentration was 1% for in all wells. Compounds were evaluated in both the immunostain assay and in the cell viability assay.

Data Analysis: Thirty two control wells containing cells only, 24 wells containing Hyamine and 8 wells containing ALLN were included on each assay plate and used to calculate Z' value for each plate and to normalize the data on a per plate basis. Data were analyzed using the IDBS Activity Base software. Results were expressed as Fold Increase (FI) for the immunostain assay and cell viability (V) for the alamarBlue assay. Final data was reported as Normalized fold increase (NFI). Data was analyzed as follows FI=DataValue/Median cell control, V= (DataValue-median Hyamine control)/(median cell control -median Hyamine control) and NFI=FI/V.

For the immunostain dose response assay, IC50 values were calculated for active compounds by plotting the FI for each concentration, and using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0. Similarly, EC50 values were calculated for the cell viability dose response assay, plotting the % Viability at each concentration and also using a 4 parameter Levenburg-Marquardt algorithm with the minimum limit set at 0 and the maximum limit set at 100.

Outcome- From the primary screen, compounds selected as Active were those that met one of the following two criteria: (1) Fold Induction >/= 1.5, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/= 1.5; or (2) Fold Induction >/= 1, Cell Viability >/= 50% and the ratio of Fold Induction to Cell Viability >/=1.75. While 101 compounds met this criteria, 96 were ultimately selected for confirmatory screening. For the dose response screen, compounds were labeled as "Active" if they showed at least 8 fold increase over the ALLN control at any concentration.
Comment: Possible Artifacts: Possible artifacts in this assay include, but are not limited to, compounds that are fluorescent, absorb at the excitation or emission wavelengths, or non-specifically upregulate protein expression
IC50 ModifierIC50IC50 Fit Hill SlopeIC50 Fit NormChi2IC50 Fit StDevMax Fold IncreaseConc @Max Fold IncreaseEC50 ModifierEC50EC50 Fit Hill SlopeEC50 Fit NormChi2EC50 Fit StDevFold Increase @50 uM Rep1Fold Increase @25 uM Rep1Fold Increase @12.5 uM Rep1Fold Increase @6.25 uM Rep1Fold Increase @3.13 uM Rep1Fold Increase @1.56 uM Rep1Fold Increase @0.78 uM Rep1Fold Increase @0.39 uM Rep1Fold Increase @0.2 uM Rep1Fold Increase @0.09 uM Rep1Fold Increase @20 ug/ml Rep1Fold Increase @10 ug/ml Rep1Fold Increase @5 ug/ml Rep1Fold Increase @2.5 ug/ml Rep1Fold Increase @1.25 ug/ml Rep1Fold Increase @0.63 ug/ml Rep1Fold Increase @0.31 ug/ml Rep1Fold Increase @0.156 ug/ml Rep1Fold Increase @0.078 ug/ml Rep1Fold Increase @0.039 ug/ml Rep1Fold Increase @50 uM Rep2Fold Increase @25 uM Rep2Fold Increase @12.5 uM Rep2Fold Increase @6.25 uM Rep2Fold Increase @3.13 uM Rep2Fold Increase @1.56 uM Rep2Fold Increase @0.78 uM Rep2Fold Increase @0.39 uM Rep2Fold Increase @0.2 uM Rep2Fold Increase @0.09 uM Rep2Fold Increase @20 ug/ml Rep2Fold Increase @10 ug/ml Rep2Fold Increase @5 ug/ml Rep2Fold Increase @2.5 ug/ml Rep2Fold Increase @1.25 ug/ml Rep2Fold Increase @0.63 ug/ml Rep2Fold Increase @0.31 ug/ml Rep2Fold Increase @0.156 ug/ml Rep2
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Mus musculus
External ID: CHEMBL840875
Protocol: N/A
Comment: Journal: J Med Chem
Year: 2000
Volume: 43
Issue: 11
First Page: 2204
Last Page: 2216
DOI: 10.1021/jm990968+

Target ChEMBL ID: CHEMBL375
ChEMBL Target Name: Mus musculus
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
PermeabilityPermeable
Permeability
PermeabilityPermeable
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Pleiotropic ABC efflux transporter of multiple drugs
External ID: CHEMBL1696822
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Antimicrob Agents Chemother
Year: 2009
Volume: 53
Issue: 4
First Page: 1516
Last Page: 1527
DOI: 10.1128/aac.00956-08

Target ChEMBL ID: CHEMBL1697658
ChEMBL Target Name: Pleiotropic ABC efflux transporter of multiple drugs
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
57INH=57uM
96INH=96uM
6.4INH=6.4uM
47INH=47uM
285INH=285uM
5.4INH=5.4uM
7.2INH=7.2uM
4.2INH=4.2uM
433INH>433uM
26INH=26uM
433INH>433uM
5.6INH=5.6uM
128INH=128uM
1.9INH=1.9uM
331INH=331uM
101INH=101uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1696823
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Antimicrob Agents Chemother
Year: 2009
Volume: 53
Issue: 4
First Page: 1516
Last Page: 1527
DOI: 10.1128/aac.00956-08
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
57INH=57uM
278INH=278uM
17.2INH=17.2uM
49INH=49uM
275INH=275uM
12.4INH=12.4uM
11INH=11uM
4.3INH=4.3uM
433INH>433uM
53INH=53uM
433INH>433uM
9.4INH=9.4uM
252INH=252uM
1.9INH=1.9uM
317INH=317uM
273INH=273uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3372306
Protocol: N/A
Comment: Journal: Eur. J. Med. Chem.
Year: 2014
Volume: 87
First Page: 429
Last Page: 439
DOI: 10.1016/j.ejmech.2014.09.081
Standard TypeStandard RelationStandard ValueStandard Units
Peff=0.3710'-6 cm/s
Peff=0.7810'-6 cm/s
Peff=610'-6 cm/s
Peff=16.410'-6 cm/s
Peff=0.2410'-6 cm/s
Peff=17.710'-6 cm/s
Peff=0.3710'-6 cm/s
Peff=14.310'-6 cm/s
Peff=5.110'-6 cm/s
Peff=0.2610'-6 cm/s
Peff=21.210'-6 cm/s
Peff=22.310'-6 cm/s
Peff=0.6510'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1052384
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2009
Volume: 52
Issue: 17
First Page: 5365
Last Page: 5379
DOI: 10.1021/jm900859q
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
permeability=3.110'-6 cm/s
permeability=19.210'-6 cm/s
permeability=8.510'-6 cm/s
permeability=22.910'-6 cm/s
permeability=2.510'-6 cm/s
permeabilityNot Determined
permeability=4.310'-6 cm/s
permeability=13.210'-6 cm/s
permeability=4.710'-6 cm/s
permeability=10.210'-6 cm/s
permeability=4.710'-6 cm/s
permeability=8.810'-6 cm/s
permeability=26.710'-6 cm/s
permeability=27.610'-6 cm/s
permeability=4.910'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Snq2p
External ID: CHEMBL1696824
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Antimicrob Agents Chemother
Year: 2009
Volume: 53
Issue: 4
First Page: 1516
Last Page: 1527
DOI: 10.1128/aac.00956-08

Target ChEMBL ID: CHEMBL1697660
ChEMBL Target Name: Snq2p
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: H - Homologous protein target assigned
Confidence: Homologous single protein target assigned
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
32INH=32uM
131INH=131uM
13.1INH=13.1uM
47INH=47uM
117INH=117uM
8.8INH=8.8uM
6.6INH=6.6uM
5.8INH=5.8uM
90INH=90uM
22INH=22uM
433INH>433uM
3.2INH=3.2uM
100INH=100uM
2.1INH=2.1uM
239INH=239uM
100INH=100uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1052382
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2009
Volume: 52
Issue: 17
First Page: 5365
Last Page: 5379
DOI: 10.1021/jm900859q
Standard TypeStandard RelationStandard ValueStandard Units
permeability=0.810'-6 cm/s
permeability=1310'-6 cm/s
permeability=6.510'-6 cm/s
permeability=1210'-6 cm/s
permeability=2.510'-6 cm/s
permeability=9.310'-6 cm/s
permeability=1.110'-6 cm/s
permeability=8.810'-6 cm/s
permeability=1.310'-6 cm/s
permeability=5.310'-6 cm/s
permeability=0.910'-6 cm/s
permeability=5.110'-6 cm/s
permeability=1610'-6 cm/s
permeability=1710'-6 cm/s
permeability=1.910'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1052383
Protocol: N/A
Comment: Journal: J. Med. Chem.
Year: 2009
Volume: 52
Issue: 17
First Page: 5365
Last Page: 5379
DOI: 10.1021/jm900859q
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
permeability=2.610'-6 cm/s
permeability=22.310'-6 cm/s
permeability=13.610'-6 cm/s
permeability=24.410'-6 cm/s
permeability=310'-6 cm/s
permeability=26.110'-6 cm/s
permeability=2.810'-6 cm/s
permeability=22.410'-6 cm/s
permeability=4.410'-6 cm/s
permeability=14.110'-6 cm/s
permeability=4.210'-6 cm/s
permeability=6.410'-6 cm/s
permeability=28.310'-6 cm/s
permeability=38.910'-6 cm/s
permeability=4.910'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3301363
Protocol: N/A
Comment: Data Source: AstraZeneca DMPK/physicochemical
Standard TypeStandard Value
LogD7.41.56
LogD7.41.39
LogD7.4-0.78
LogD7.42.22
LogD7.43
LogD7.41.91
LogD7.4-0.84
LogD7.41.19
LogD7.4-1.08
LogD7.43.08
LogD7.43.65
LogD7.4-0.5
LogD7.42.43
LogD7.42.3
LogD7.43.65
LogD7.44.3
LogD7.43.26
LogD7.42.55
LogD7.41.69
LogD7.41.46
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3301365
Protocol: N/A
Comment: Data Source: AstraZeneca DMPK/physicochemical
Standard TypeStandard ValueStandard Units
PPB96%
PPB34.42%
PPB87.87%
PPB79.55%
PPB55.73%
PPB99.91%
PPB98.61%
PPB99.81%
PPB87.11%
PPB96.26%
PPB92.32%
PPB66.1%
PPB75.97%
PPB99.19%
PPB62.4%
PPB30.88%
PPB71.99%
PPB98.37%
PPB92.64%
PPB95.72%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL1929957
Protocol: N/A
Comment: Journal: Eur. J. Med. Chem.
Year: 2012
Volume: 47
First Page: 175
Last Page: 185
DOI: 10.1016/j.ejmech.2011.10.040
Standard TypeStandard RelationStandard ValueStandard Units
permeability=1.310'-6 cm/s
permeability=0.410'-6 cm/s
permeability=15.710'-6 cm/s
permeability=1.810'-6 cm/s
permeability=7.710'-6 cm/s
permeability=1.710'-6 cm/s
permeability=1.210'-6 cm/s
permeability=15.210'-6 cm/s
permeability=15.210'-6 cm/s
permeability=2.310'-6 cm/s
permeability=23.810'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3123849
Protocol: N/A
Comment: Journal: Eur. J. Med. Chem.
Year: 2014
Volume: 73
First Page: 141
Last Page: 152
DOI: 10.1016/j.ejmech.2013.12.008
Standard TypeStandard RelationStandard ValueStandard Units
permeability=0.8ucm/s
permeability=0.1ucm/s
permeability=12.3ucm/s
permeability=0ucm/s
permeability=12ucm/s
permeability=1.71ucm/s
permeability=9.3ucm/s
permeability=0.75ucm/s
permeability=8.8ucm/s
permeability=5.3ucm/s
permeability=5.1ucm/s
permeability=16ucm/s
permeability=17ucm/s
permeability=1.4ucm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:IUPHAR-DB 靶标:D2 receptor (Dopamine receptors) [Homo sapiens]
External ID: 215_Human
Protocol: The International Union of Basic and Clinical Pharmacology/British Pharmacological Society (IUPHAR/BPS) Guide to PHARMACOLOGY Database (GtoPdb) uses expert subcommittees to collate peer-reviewed information from the published literature regarding individual protein targets, and describes the pharmacology, genetics, function and anatomy of each target. Its pages provide a richly curated overview of the pharmacology of receptors, ion channels, enzymes and other target types, which can be found by following the external link to the GtoPdb website.

Comment: The data collected focuses on ligands at human receptors. Data are provided at rat or mouse orthologues where there are significant species differences, or where data are not yet available at the human target.

Information on individual experimental protocols can be found in the primary references listed for each ligand.

Affinity data are expressed as pKi [-log(Ki)], pKd [-log(Kd)], pIC50 [-log(IC50)], pEC50 [-log(EC50)], pKB [-log(KB)], pA2 or as a micromolar concentration range. In most cases the original concentration can be found in the primary reference.
pKi_minpKi_maxpKd_minpKd_maxpIC50_minpIC50_maxpEC50_minpEC50_maxpKB_minpKB_maxTypeActionReference (PubMed ID)
9.99.9AntagonistAntagonist15686911
8.28.2AgonistBiased agonist24755247
77AntagonistAntagonist24666157,24260782
5.65.6AgonistFull agonist7990123
6.47.1AntagonistAntagonist1975644,8301582
8.78.7AntagonistAntagonist15357957
6.96.9AntagonistAntagonist8301582
5.46.4AgonistFull agonist7756621,8531103
4.77.2AgonistFull agonist7756621,7576010,8301582
6.86.8AgonistAgonist18800769
8.78.7AntagonistAntagonist9430133
88AntagonistAntagonist8935801
8.99.6AntagonistAntagonist12629531
7.17.18.28.2AgonistBiased agonist22025698
7.48.8AntagonistAntagonist7907989,1354163,7664822,7862709,8301582
9.79.7AntagonistAntagonist1586393
9.49.4AntagonistAntagonist9430133
6.86.9AgonistPartial agonist12388666
8.68.699AgonistBiased agonist22025698
6.76.7AgonistAgonist17649988
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3094590
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2013
Volume: 21
Issue: 23
First Page: 7406
Last Page: 7417
DOI: 10.1016/j.bmc.2013.09.050
Standard TypeStandard RelationStandard ValueStandard Units
permeability=0.8ucm/s
permeability=0.8ucm/s
permeability=6.5ucm/s
permeability=12ucm/s
permeability=2.5ucm/s
permeability=9.3ucm/s
permeability=1.1ucm/s
permeability=8.8ucm/s
permeability=5.3ucm/s
permeability=0.1ucm/s
permeability=16ucm/s
permeability=17ucm/s
permeability=1.9ucm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3094591
Protocol: N/A
Comment: Journal: Bioorg. Med. Chem.
Year: 2013
Volume: 21
Issue: 23
First Page: 7406
Last Page: 7417
DOI: 10.1016/j.bmc.2013.09.050
Standard TypeStandard RelationStandard ValueStandard Units
permeability=0.37ucm/s
permeability=0.78ucm/s
permeability=6ucm/s
permeability=16.4ucm/s
permeability=0.24ucm/s
permeability=17.7ucm/s
permeability=0.37ucm/s
permeability=14.3ucm/s
permeability=5.1ucm/s
permeability=0.26ucm/s
permeability=21.2ucm/s
permeability=22.3ucm/s
permeability=0.65ucm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4050057
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2017
Volume: 130
First Page: 60
Last Page: 72
DOI: 10.1016/j.ejmech.2017.02.034
Standard TypeStandard RelationStandard ValueStandard UnitsActivity Comment
permeability=2.310'-6 cm/s
permeability=14.410'-6 cm/s
permeabilityNot Determined
permeability=1110'-6 cm/s
permeability=16.210'-6 cm/s
permeabilityNot Determined
permeability=3.710'-6 cm/s
permeability=17.710'-6 cm/s
permeability=2.510'-6 cm/s
permeability=15.510'-6 cm/s
permeability=4.310'-6 cm/s
permeability=9.510'-6 cm/s
permeability=2.610'-6 cm/s
permeability=6.410'-6 cm/s
permeability=20.210'-6 cm/s
permeability=24.510'-6 cm/s
permeability=510'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL4050058
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2017
Volume: 130
First Page: 60
Last Page: 72
DOI: 10.1016/j.ejmech.2017.02.034
Standard TypeStandard RelationStandard ValueStandard Units
permeability=0.810'-6 cm/s
permeability=1310'-6 cm/s
permeability=6.510'-6 cm/s
permeability=1210'-6 cm/s
permeability=2.510'-6 cm/s
permeability=9.310'-6 cm/s
permeability=1.110'-6 cm/s
permeability=8.810'-6 cm/s
permeability=1.310'-6 cm/s
permeability=5.310'-6 cm/s
permeability=0.910'-6 cm/s
permeability=5.110'-6 cm/s
permeability=1610'-6 cm/s
permeability=1710'-6 cm/s
permeability=1.910'-6 cm/s
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: SERCaMPGLuc-p1-antagonist
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 5 uL; 1000 SH-SY5Y cells per wells
2; Time; 5 hour; 37C, 5% CO2
3; Compound; 23 nL; Control inhibitor / compound library
4; Time; 16 hour; 37C, 5% CO2
5; Reagent; 100 nM; Thapsigargin
6; Time; 4 hour; 37C, 5% CO2
7; Reagent; 1 uL; 0.5x coelenterazine
8; Detection; Luminescence; ViewLux imaging system

NOTES (numbers refer to sequence above)
1; SH-SY5Y human neuroblastoma cells stably expressing GLuc-SERCaMP (SH-SY5Y-GLuc-ASARTDL) cells were seeded in 1,536 well white tissue culture treated plates (Corning, Cat# 7464) in DMEM-high glucose-sodium pyruvate (ThermoFisher Scientific, Cat #10569) supplemented with 10% bovine growth serum (Hyclone), 10 U/ml penicillin (Gibco), 10 ug/ml streptomycin (Gibco), and 20 mM HEPES.
2; Assay plates were incubated for 5 hour at 37C in a humidified incubator containing 5% CO2.
3; qHTS libraries (23 nl, final concentrations of 1.53 uM, 7.67 uM, 38.3 uM) or controls (neutral control: DMSO, positive control: dantrolene) were added using a Kalypsis pin-tool Robotic System equipped with 1536 pinheads.
4; Cells were then incubated for 16 hours at 37C, 5% CO2.
5; Thapsigargin was added at 100 nM to deplete ER calcium stores.
6; Cells were incubated for 4 hour (37oC, 5% CO2)
7; Gaussia luciferase in the medium was measured by adding 1 ul of 0.5x coelenterazine (final concentration 0.07x) prepared in Gaussia Luciferase Glow Assay Buffer (Pierce), without addition of the Cell Lysis Buffer Reagent.
8; Luminescence was measured using a ViewLux high-432 throughput CCD imaging system (Perkin Elmer) equipped with clear filters. Compounds exhibiting inhibitory activity (defined as curve class -1.1, -1.2, -1.3, -1.4, -2.1, -2.2, -2.3, -2.4, -3) were identified by normalizing plate-wise to corresponding intra-plate controls (neutral control = Tg only; positive control (100% inhibition) = DMSO vehicle) with percent activity derived using in-house software (https://tripod.nih.gov/curvefit). The same controls were also used for the calculation of the Z' factor, a measure of assay quality control, as previously described (Zhang et al., 1999). For the initial validation of activity in the SERCaMP assays, hits from the primary screen were assayed again at 11-concentrations (1.3 nM - 76.6 uM). SH-SY5Y-GLuc-SERCaMP cells were assayed for ER Ca2+ depletion as outlined above.

Reference:
1. Zhang, J.H., Chung, T.D., and Oldenburg, K.R. (1999). A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4, 67-73.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000259387 uMActivity at 0.0000710850 uMActivity at 0.0001271514 uMActivity at 0.0003024044 uMActivity at 0.0005030064 uMActivity at 0.0006524306 uMActivity at 0.00193 uMActivity at 0.00341 uMActivity at 0.00584 uMActivity at 0.010 uMActivity at 0.018 uMActivity at 0.052 uMActivity at 0.078 uMActivity at 0.156 uMActivity at 0.276 uMActivity at 0.478 uMActivity at 0.883 uMActivity at 1.507 uMActivity at 3.884 uMActivity at 7.354 uMActivity at 12.96 uMActivity at 21.63 uMActivity at 38.41 uMActivity at 76.33 uMActivity at 137.0 uMActivity at 204.0 uMCompound QC
Inhibitor1104.966488Complete curve; high efficacy-63.51170.6658-104.96640-1.10 0 0-97.13-85.6484-112.8671-97.13QC'd by Tocris
Inhibitor0.316259.327888Complete curve; high efficacy-6.50.81-84.7193-25.3915-1.10 0 0-83.9327-75.7429-81.922-83.9327QC'd by BIOMOL
Inhibitor3.162320.498785Complete curve; high efficacy-5.54.95490.4756-107.8212-87.3224-1.10 0 0-101.1849-96.9354-114.4343-101.1849QC'd by SIGMA
Inhibitor0.749266.151166Complete curve; partial efficacy-6.125410.8229-74.6135-8.4624-1.20 0 0 0 0 0 0 0 0 0 0-67.099-7.8787-22.7216-1.4525-29.6562-23.5194-8.332-25.0891-62.4832-68.6466-63.9027-67.099QC'd by Microsource
Inhibitor121.684566Complete curve; partial efficacy-64.95490.9699-77.7873-56.1028-1.20 0 0-76.43-65.0857-78.9894-76.43QC'd by BIOMOL
Inhibitor1.12259.675865Complete curve; partial efficacy-5.951.210.9999-66.8495-7.1736-1.20 0 0-66.096-42.6313-61.4055-66.096QC'd by Vitas
Inhibitor1.995334.026364Complete curve; partial efficacy-5.74.95490.9891-73.9118-39.8855-1.20 0 0-72.1972-47.1162-75.3813-72.1972QC'd by SigmaAldrich
Inhibitor12.589337.266562Complete curve; partial efficacy-4.911-78.1117-40.8452-1.20 0 0-68.8431-44.9463-54.9089-68.8431QC'd by Tocris
Inhibitor14.125432.429762Complete curve; partial efficacy-4.851.22160.9999-88.7022-56.2725-1.20 0 0-81.3177-58.1227-66.7029-81.3177QC'd by Enzo
Inhibitor1029.898362Complete curve; partial efficacy-53.29750.9999-76.1051-46.2067-1.20 0 0-75.9694-46.234-54.866-75.9694QC'd by Microsource
Inhibitor11.220226.849761Complete curve; partial efficacy-4.954.0950.9996-65.1082-38.2585-1.20 0 0-65.0072-38.2023-43.2866-65.0072QC'd by SigmaAldrich
Inhibitor25.118945.784461Complete curve; partial efficacy-4.61.53861-101.459-55.6745-1.20 0 0-85.8367-56.2934-62.0903-85.8367QC'd by SigmaAldrich
Inhibitor31.622832.29860Complete curve; partial efficacy-4.52.18760.9999-141.8428-109.5448-1.20 0 0-129.0357-109.6207-111.066-129.0357QC'd by Microsource
Inhibitor31.622835.977260Complete curve; partial efficacy-4.51.10.9999-99.0432-63.0659-1.20 0 0-82.9526-64.2216-69.1965-82.9526QC'd by Microsource
Inhibitor35.481337.624260Complete curve; partial efficacy-4.454.95490.9762-81.2779-43.6537-1.20 0 0-66.0936-45.7944-41.8015-66.0936QC'd by Tocris
Inhibitor35.481350.188560Complete curve; partial efficacy-4.454.44950.9982-87.6877-37.4992-1.20 0 0-66.8089-38.2236-36.8414-66.8089QC'd by Pharmacopeia
Inhibitor35.481347.340560Complete curve; partial efficacy-4.454.95490.9906-107.1544-59.8139-1.20 0 0-87.9757-61.3159-58.1701-87.9757QC'd by Prestwick Chemical; Inc.
Inhibitor5.9508124.625145Partial curve; high efficacy-5.22542.72020.864-126.7319-2.1068-2.10 0 0 0 0 0 0 0 0 0 1000-13.748-1.3723-25.9483-11.282526.65188.4521-36.83-113.80310QC'd by ChemAxon
Inhibitor11.873489.544142Partial curve; partial efficacy-4.92541.24750.9863-91.1278-1.5837-2.20 0 0 0 0 1 0 0 0 0 0-74.7046000-4.6868-8.0974-38.15161.1319-8.2196-21.8072-47.3218-74.7046QC'd by Cayman
Inhibitor25.1189267.383841Partial curve; partial efficacy-4.64.95490.8835-100.7065166.6773-2.20 0 0-71.9482116.4983215.4265-71.9482QC'd by Tocris
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Plasmodium falciparum
External ID: CHEMBL3392944
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL364
ChEMBL Target Name: Plasmodium falciparum
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Drugs for Neglected Diseases Initiative (DNDi)
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
1.48IC50=1480nM
29.17IC50=29170nM
9.85IC50=9850nM
1.44IC50=1440nM
0.58IC50=580nM
1.76IC50=1760nM
36.46IC50>36460nM
246.46IC50=246460nMOutside typical range
38.26IC50=38260nM
3.03IC50=3030nM
0.17IC50=170nM
0.49IC50=490nM
0.75IC50=750nM
0.11IC50=110nM
75.12IC50=75120nM
2.72IC50=2720nM
3.18IC50=3180nM
15.17IC50=15170nM
17.21IC50=17210nM
4.35IC50=4350nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:ubiquitin carboxyl-terminal hydrolase 2 isoform a [Homo sapiens]
External ID: UBCH001
Protocol: NCGC Assay Protocol Summary:

The assay buffer, prepared fresh at the day of the assay, contains 20mM Tris-HCl pH 8.0, 2mM CaCl2, 2mM beta-Mercaptoethanol, 0.05% CHAPS. 3ul of 20nM (10nM final) USP2 core, which is stored on ice, is dispensed into a medium-binding black solid Kalypsys 1,536 well plate using the Kalypsys dispenser. The assay plate is then pinned with 23nL compound with the Kalypsys pintool in columns 5-48. The controls are pinned as follows: column 1 two-fold dilutions of 2M NEM in duplicate; column 2 2M NEM (final concentration 38.2mM); column 3&4 DMSO. The assay plate is incubated at RT for 30min. Subsequently, 1.5uL of 100nM (25nM final) Ub-CHOP2 and 1.5uL of 100nM (25nM final) Reporter Substrate (both stored on ice and protected from light) were dispensed into the plate using the Kalypsys dispenser. Plates were read after 60min RT incubation on a ViewLux (Perkin Elmer) plate reader using the following wavelengths Ex 485nm /Em 531nm.

Data were normalized to the to AC100 inhibition (NEM). Concentration-response curves were fitted to the normalized data and the concentration-response curves were then classified based on curve quality (r2), response magnitude and degree of measured activity. The time zero reading was used to flag fluorescence artifacts.

Keywords: ubiquitination, deubiquitination, proteases, profluorescent, MLSMR, MLPCN, NIH Roadmap, qHTS, NCGC
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description".
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 20 and 39. Fluoresent compounds have PUBCHEM_ACTIVITY_SCORE 10. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00245 uMActivity at 0.012 uMActivity at 0.061 uMActivity at 0.307 uMActivity at 1.530 uMActivity at 7.660 uMActivity at 38.30 uMCompound QC
Inactive4-0.88650.25092.49153.1941-1.15443.46670.6782-0.8865QC'd by "SigmaAldrich"
Inactive4-0.63722.324-0.91860.1155-1.00433.95670.1609-0.6372QC'd by "SigmaAldrich"
Inactive4-0.7336-0.772.34313.66752.17582.0377-0.7322-0.7336QC'd by "SigmaAldrich"
Inactive42.98811.0501-0.67341.3801-0.78681.35943.36462.9881QC'd by "SigmaAldrich"
Inactive43.57330.75523.36021.47890.6751-0.6617-0.18943.5733QC'd by "SigmaAldrich"
Inactive4-0.52240.8941-1.0519-0.27530.8983-2.99510.1575-0.5224QC'd by "SigmaAldrich"
Inactive40.4211-0.80260.88041.35873.19810.53780.55540.4211QC'd by "SigmaAldrich"
Inactive40 0 0 0 0 0 00.6469-5.76070.770.293-2.581.0974-2.45760.6469QC'd by "SigmaAldrich"
Inactive4-0.33321.4141-1.1668-1.46313.72-1.7652.6621-0.3332QC'd by "SigmaAldrich"
Inactive4-1.1862.3757-0.95621.2867-1.2502-0.14931.2592-1.186QC'd by "SigmaAldrich"
Inactive41.2081.1170.36511.32752.052-1.06352.33481.208QC'd by "SigmaAldrich"
Inactive40.07930.40473.10143.9029-2.18654.6116-1.3530.0793QC'd by "SigmaAldrich"
Inactive40.7828-1.0257-0.54621.88191.9384-0.48750.72350.7828QC'd by "SigmaAldrich"
Inactive4-0.75863.12143.4856-1.4684-1.168-0.895-1.1824-0.7586QC'd by "SigmaAldrich"
Inactive41.57212.2029-0.69990.0703-1.30151.00141.76571.5721QC'd by "SigmaAldrich"
Inactive4-1.48271.2970.0838-0.11081.28220.8665-0.8887-1.4827QC'd by "SigmaAldrich"
Inactive40.54761.78040.09661.45344.561.4925-0.35660.5476QC'd by "SigmaAldrich"
Inactive4-0.50540.7652-0.30831.91420.3654-0.670.809-0.5054QC'd by "SigmaAldrich"
Inactive40 0 0 0 0 0 0-12.8672.7421.10850.61751.40611.3876-0.3224-12.867QC'd by "SigmaAldrich"
Inactive4-2.3614-0.37611.4090.34630.50031.94862.0251-2.3614QC'd by "SigmaAldrich"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NON-PROTEIN TARGET
External ID: CHEMBL3392938
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL3879801
ChEMBL Target Name: NON-PROTEIN TARGET
ChEMBL Target Type: NON-MOLECULAR - Target has not been defined at a molecular level, only the non-molecular entity which is affected (e.g., organism, cell line etc)
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Drugs for Neglected Diseases Initiative (DNDi)
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
10.99IC50=10990nM
301.57IC50=301570nMOutside typical range
2.51IC50=2510nM
20.62IC50=20620nM
27.87IC50=27870nM
8.87IC50=8870nM
54.36IC50=54360nM
656.26IC50>656260nMOutside typical range
602.3IC50=602300nMOutside typical range
116.19IC50=116190nMOutside typical range
12.32IC50=12320nM
50.61IC50=50610nM
15.44IC50=15440nM
147.04IC50=147040nMOutside typical range
2.99IC50=2990nM
293.85IC50>293850nMOutside typical range
30.06IC50=30060nM
18.5IC50=18500nM
90.31IC50=90310nM
39.3IC50=39300nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:NON-PROTEIN TARGET
External ID: CHEMBL3392939
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL3879801
ChEMBL Target Name: NON-PROTEIN TARGET
ChEMBL Target Type: NON-MOLECULAR - Target has not been defined at a molecular level, only the non-molecular entity which is affected (e.g., organism, cell line etc)
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Drugs for Neglected Diseases Initiative (DNDi)
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
24.54IC50=24540nM
118.89IC50>118890nMOutside typical range
12.06IC50>12060nM
40.12IC50=40120nM
37.97IC50=37970nM
29.37IC50>29370nM
75.86IC50>75860nM
218.75IC50>218750nMOutside typical range
218.75IC50>218750nMOutside typical range
60.73IC50>60730nM
31.36IC50=31360nM
58.85IC50>58850nM
62.74IC50=62740nM
96.95IC50>96950nM
87IC50=87000nM
97.95IC50>97950nM
35.16IC50>35160nM
28.38IC50=28380nM
125.44IC50=125440nMOutside typical range
32.22IC50>32220nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Trypanosoma cruzi
External ID: CHEMBL3392937
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL368
ChEMBL Target Name: Trypanosoma cruzi
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Drugs for Neglected Diseases Initiative (DNDi)
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
10.13IC50=10130nM
351.11IC50=351110nMOutside typical range
5.71IC50=5710nM
24.87IC50=24870nM
22.89IC50=22890nM
4.44IC50=4440nM
64.58IC50=64580nM
656.26IC50>656260nMOutside typical range
382.82IC50=382820nMOutside typical range
93.93IC50=93930nM
17.15IC50=17150nM
99.25IC50=99250nM
0.04IC50=40nM
141IC50=141000nMOutside typical range
0.006IC50=6nM
9.96IC50=9960nM
49.15IC50=49150nM
15.01IC50=15010nM
4.35IC50=4350nM
0.003IC50=3nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Leishmania donovani
External ID: CHEMBL3392942
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL367
ChEMBL Target Name: Leishmania donovani
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Drugs for Neglected Diseases Initiative (DNDi)
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
52.93IC50=52930nM
396.28IC50>396280nMOutside typical range
277.83IC50=277830nMOutside typical range
125.57IC50=125570nMOutside typical range
341.71IC50>341710nMOutside typical range
19.77IC50=19770nM
227.57IC50>227570nMOutside typical range
656.26IC50>656260nMOutside typical range
729.18IC50>729180nMOutside typical range
9.8IC50=9800nM
48.45IC50=48450nM
196.15IC50>196150nMOutside typical range
4.39IC50=4390nM
290.86IC50>290860nMOutside typical range
2.23IC50=2230nM
210.59IC50=210590nMOutside typical range
316.43IC50>316430nMOutside typical range
79.79IC50=79790nM
2.12IC50=2120nM
5.48IC50=5480nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Leishmania donovani
External ID: CHEMBL3392943
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL367
ChEMBL Target Name: Leishmania donovani
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Drugs for Neglected Diseases Initiative (DNDi)
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
7.36IC50>7360nM
118.89IC50>118890nMOutside typical range
12.06IC50>12060nM
12.04IC50>12040nM
11.39IC50>11390nM
2.63IC50=2630nM
75.86IC50>75860nM
218.75IC50>218750nMOutside typical range
218.75IC50>218750nMOutside typical range
60.73IC50>60730nM
9.41IC50>9410nM
58.85IC50>58850nM
10.79IC50=10790nM
96.95IC50>96950nM
14.67IC50=14670nM
97.95IC50>97950nM
35.16IC50>35160nM
8.51IC50>8510nM
41.81IC50>41810nM
32.22IC50>32220nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: cib1-v1-fp-lopac
Protocol: PROTOCOL TABLES
SEQUENCE No. (1, 2, 3, etc.); PARAMETER (e.g., Cells, Incubation, Reagent, etc.); VALUE and DESCRIPTION.
1; Reagent; 3 uL; Protein or buffer (4/3x)
2; Compound; 46 nL; Control inhibitor / compound library
3; Time; 15 min; Room temperature incubation
4; Reagent; 1 uL; Fluorescent labeled peptide (4x)
5; Time; 1000 rpm; Centrifuge
6; Time; 15 min; Room temperature incubation
7; Detection; Ex 480/ Em 540; ViewLux Fluorescence Read

NOTES (numbers refer to sequence above)
1; Protein Mixture: C1B1-GST (final concentrations of 1 uM). Buffer composition: 5 mM HEPES pH 7.4, 125 mM NaCl, 5 mM CaCl2, 0.01% Tween20.
2; Control Inhibitor: unlabeled peptide (final concentration range 17.4 nM to 572 uM). Compound Library final concentration range 18.3 nM to 114 uM.
3; Room temperature incubation.
4; Fluorescent Labeled Peptide: FITC-aIIb (final concentration of 100 nM). Sequence of alphaIIb peptide: Acetyl-LVLAMWKVGFFKRNRK-FITC (purity is 95.83%).
5; Centrifuge 1000 rpm (164 g) for 15 seconds.
6; Room temperature incubation.
7; ViewLux Fluorescent Polization Read: excitation = 480(20) / emission = 540(25) S and P; FITC Dichroic mirror.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.457 uMActivity at 2.290 uMActivity at 11.40 uMActivity at 57.10 uMActivity at 114.0 uMCompound QC
Inactive00047.97775.218613.21832.88075.14317.9777QC'd by SIGMA
Inactive0-5.254.95490.78024.510.540 0 0 0 04.81458.380612.50713.21345.47894.8145QC'd by SIGMA
Inactive0-6.254.95490.6118-2.10793.540 0 0 0 10.77892.0284-4.2566-1.0182-0.59080.7789QC'd by SIGMA
Inactive00043.57742.38233.86868.2512.01483.5774QC'd by SIGMA
Inactive000410.38079.895.918111.4919.356810.3807QC'd by SIGMA
Inactive0-4.34.95490.6272-4.04822.540 0 0 0 12.42543.92840.19853.7517-1.70682.4254QC'd by SIGMA
Inactive0-6.253.92950.7726-0.60696.540 0 0 0 0-2.58914.3389-1.0785-0.00880.7325-2.5891QC'd by SIGMA
Inactive0-4.110.6094151.257540 0 0 0 011.0674.8012-0.61874.74545.008111.067QC'd by SIGMA
Inactive0-5.80.50.99370.51040 0 0 0 01.4316.82144.5993.16091.62171.431QC'd by SIGMA
Inactive0-5.753.51170.334511.5840 0 0 0 011.16748.067810.485814.2068.429611.1674QC'd by SIGMA
Activator44.668417.50Partial curve; partial efficacy; poor fit-4.350.30.5917213.52.40 0 0 0 015.9596.6539.006811.64018.938815.959QC'd by SIGMA
Inactive00045.8632.93888.37043.67094.32195.863QC'd by SIGMA
Inactive0-44.0950.4043-2.8717240 0 0 0 0-1.14311.3342-0.17344.61831.5532-1.1431QC'd by SIGMA
Inactive0-6.254.95490.516310.5540 0 0 0 09.78116.559812.035911.67457.82369.7811QC'd by SIGMA
Inactive000411.14538.912711.250616.76477.346711.1453QC'd by SIGMA
Inactive0-5.354.95490.621211440 0 0 0 09.27045.61082.505315.32668.369.2704QC'd by SIGMA
Inactive0-44.95490.5331-4.83282.540 0 0 0 0-2.36060.78591.09176.05482.0406-2.3606QC'd by SIGMA
Inactive0-5.354.95490.96150.5095.540 0 0 0 00.67935.52425.628-0.40921.0110.6793QC'd by SIGMA
Inactive0-6.254.95490.86260.449940 0 0 0 01.79316.6174-0.87580.7592-0.83651.7931QC'd by SIGMA
Inactive0-4.33.92950.7001-3.73360.540 0 0 0 0-3.5281.1629-1.35772.2632-2.0565-3.528QC'd by SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Trypanosoma brucei rhodesiense
External ID: CHEMBL3392941
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Target ChEMBL ID: CHEMBL612348
ChEMBL Target Name: Trypanosoma brucei rhodesiense
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: Drugs for Neglected Diseases Initiative (DNDi)
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
1.23IC50=1230nM
396.28IC50>396280nMOutside typical range
6.75IC50=6750nM
18.45IC50=18450nM
1.17IC50=1170nM
0.01IC50=10nM
22.35IC50=22350nM
656.26IC50>656260nMOutside typical range
729.18IC50>729180nMOutside typical range
87.65IC50=87650nM
1.25IC50=1250nM
3.81IC50=3810nM
36.6IC50=36600nM
15.19IC50=15190nM
23.69IC50=23690nM
273.28IC50=273280nMOutside typical range
2.16IC50=2160nM
1.42IC50=1420nM
0.5IC50=500nM
26.8IC50=26800nM